ID: MRFR/HC/6907-HCR | 100 Pages | Published By Kinjoll Dey on March 2023
Migraine Drugs Market is projected to reach USD 6986.02 million at a CAGR of 3.65% by 2030
$6986.02 million
3.65%
North America
2022-2030
Migraine Drugs Market is projected to reach USD 6986.02 million at a CAGR of 3.65% by 2030, says Market Research Future (MRFR) . Migraine is a medical ailment that is characterized by severe headaches and other symptoms such as nausea and hypersensitivity to smell. These headaches often affect only one side of the head, and each migraine episode is unique in terms of duration and intensity. Migraine medications are used to treat headaches linked with migraine.
For many years, the market for prescription acute and preventive migraine therapies has been stable — and primarily generic — but is now ready for change. The increasing prevalence of migraine fuels the demand for migraine medications. Seven or more of these high-cost, creative new medications target calcitonin gene-related peptide (CGRP), a critical pathogenic component in migraine and a long-desired, but previously elusive, therapeutic target. These are the first new migraine-specific medication classes to be introduced in almost two decades. Additionally, the growing female population and increased awareness among patients regarding migraine prevention and treatment are major drivers driving the market's growth.
However, the adverse effects associated with migraine medications act as a restraint on the market's expansion. On the contrary, the emergence of growth potential in emerging economies is projected to open up new avenues for significant participants. Additionally, hormonal drugs such as oral contraceptives and hormone replacement therapy may exacerbate migraine symptoms in females. As a result, the growing worldwide female population is expected to fuel the expansion of the migraine medications market.
The increasing prevalence of migraine is expected to contribute to the growth of the migraine drugs market during the forecast period.
Market Drivers
Market Restraints
Migraine Drugs Market Segmentation
By Type
By Treatment type
By Drug Class
By End-User
By Region
Migraine Drugs Market Key Players
Industry Updates
February 2022: Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc. published good top-line results from a Phase 3 clinical trial in 1,431 adults in Asia-Pacific evaluating rimegepant for the immediate treatment of migraine. The randomized, regional, multi-center research, led by BioShin Limited, a subsidiary of Biohaven in China and South Korea, fulfilled the co-primary endpoints evaluating the efficacy and safety of rimegepant, an oral calcitonin gene-related peptide (CGRP) receptor antagonist.
Report Attribute/Metric | Details |
---|---|
Market Size | 2030 : USD 6986.02 Billion |
CAGR | 3.65%. (2020 -2030) |
Base Year | 2019 |
Forecast Period | 2020-2027 |
Historical Data | 2018 |
Forecast Units | Value (USD Billion) |
Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered | By Type, Treatment, Drug Class, End-User |
Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
Key Vendors | Allergan Plc (Ireland), Alder Biopharmaceuticals, Inc. (US), Pfizer Inc. (US), GlaxoSmithKline Plc (UK), Merck & Co., Inc. (US), Teva Pharmaceutical Industries Ltd (Israel), AstraZeneca PLC (UK), Johnson & Johnson Services, Inc. (US), Amgen Inc. (US), Eli Lilly and Company, eNeura Inc. |
Key Market Opportunities | Rising R&D investments for the innovative drug discoveries for the treatment of the condition. |
Key Market Drivers |
|
The global migraine drugs market is projected to reach a valuation of USD 6986.02 mN by 2030.
The global migraine drugs market is projected to grow at approximately 3.65% CAGR during forecast period (2020-2030).
Rising R&D investments for the innovative drug discoveries for the treatment of the condition.
North America holds the largest share in the global migraine drugs market, followed by Europe and the Asia Pacific, respectively.
Alder Biopharmaceuticals, Inc. (US), Allergan Plc (Ireland), Pfizer Inc. (US), Merck & Co., Inc. (US), GlaxoSmithKline Plc (UK), Teva Pharmaceutical Industries Ltd (Israel), Johnson & Johnson Services, Inc. (US), AstraZeneca PLC (UK), Amgen Inc. (US), and Eli Lilly and Company eNeura Inc., are some of the major players operating in the migraine drugs market.